Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
==== Na+,K+-ATPase and Insect resistance to cardiotonic steroids ==== Many examples of convergent evolution exist in insects in terms of developing resistance at a molecular level to toxins. One well-characterized example is the evolution of resistance to cardiotonic steroids (CTSs) via amino acid substitutions at well-defined positions of the α-subunit of Na+,K+-ATPase (ATPalpha). Variation in ATPalpha has been surveyed in various CTS-adapted species spanning six insect orders. Among 21 CTS-adapted species, 58 (76%) of 76 amino acid substitutions at sites implicated in CTS resistance occur in parallel in at least two lineages. 30 of these substitutions (40%) occur at just two sites in the protein (positions 111 and 122). CTS-adapted species have also recurrently evolved neo-functionalized duplications of ATPalpha, with convergent tissue-specific expression patterns.
==== Stations ==== A Police Station is the basic unit of policing, responsible for prevention and detection of crime, maintenance of public order, enforcing law in general as well as for performing protection duties and making security arrangements for the constitutional authorities, government functionaries, representatives of the public in different legislative bodies and local self governments, public figures etc. A Police Station is headed by either a Sub-Inspector (lower subordinate rank), mostly in rural areas or an Inspector (an upper subordinate rank), mostly in urban areas. Police outposts are headed by a Sub-Inspector or Assistant Sub Inspector. After the year 2009 both ASI and SI have equal investigation power and both serve as duty officers.
== External links == somatotropin-binding+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Baumann G, Shaw MA, Winter RJ (Oct 1987). "Absence of the plasma growth hormone-binding protein in Laron-type dwarfism". The Journal of Clinical Endocrinology and Metabolism. 65 (4): 814–6. doi:10.1210/jcem-65-4-814. PMID 3654924.
They further demonstrated that increased hepatic acetyl-CoA and glycerol flux—resulting from white adipose tissue inflammation—are key drivers of elevated gluconeogenesis in rodent models of type 2 diabetes (T2D). Based on the sn-1,2 DAG–nPKC hypothesis, Shulman's laboratory developed liver-targeted mitochondrial protonophores that reduce hepatic steatosis, insulin resistance, inflammation, and fibrosis in rodent and nonhuman primate models of MASLD and MASH. These compounds have advanced to clinical evaluation.
Sources: en.wikipedia.org
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic that began in late 2019. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. SARS‑CoV‑2 is a virus of the species Betacoronavirus pandemicum (SARSr-CoV), as is SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak. Some animal-borne coronaviruses are more closely related to SARS-CoV-2 than SARS-CoV-1 is. The closest known relative is the BANAL-52 bat coronavirus. SARS-CoV-2 is of zoonotic origin; its close genetic similarity to bat coronaviruses suggests it emerged from such a bat-borne virus. Research is ongoing as to whether SARS‑CoV‑2 came directly from bats or indirectly through any intermediate hosts. The virus shows little genetic diversity, indicating that the spillover event introducing SARS‑CoV‑2 to humans is likely to have occurred in late 2019. Epidemiological studies estimate that in the period between December 2019 and September 2020 each infection resulted in an average of 2.4–3.4 new infections when no members of the community were immune and no preventive measures were taken.
== In HIV infection and immunosuppression == The suppression of CD4 T cells by HIV (or by immunosuppressive drugs) causes a decrease in the body's normal response to certain infections. Not only does this make it more difficult to fight the infection, it may mean that a level of infection that would normally produce symptoms is instead undetected (subclinical infection). If the CD4 count rapidly increases (due to effective treatment of HIV, or removal of other causes of immunosuppression), a sudden increase in the inflammatory response produces nonspecific symptoms such as fever, and in some cases a worsening of damage to the infected tissue. Though these symptoms can be dangerous, they also indicate that the body may now have a better chance to defeat the infection. The best treatment for this condition is unknown. In paradoxical IRIS reactions, the events will usually spontaneously get better with time without any additional therapy. In unmasking IRIS, the most common treatment is to administer antibiotic or antiviral drugs against the infectious organism. In some severe cases, anti-inflammatory medications, such as corticosteroids are needed to suppress inflammation until the infection has been eliminated. Infections most commonly associated with IRIS include Mycobacterium tuberculosis and cryptococcal meningitis. Persons living with AIDS are more at risk for IRIS if they are starting HAARTTooltip HAART for the first time, or if they have recently been treated for an opportunistic infection (OI).
The use of venom across a wide variety of taxa is an example of convergent evolution. In animals, venom usage has evolved independently at least 104 times, across 8 phyla. It is difficult to conclude exactly how this trait came to be so intensely widespread and diversified. The multigene families that encode the toxins of venomous animals are actively selected, creating more diverse toxins with specific functions. Also, a number of animal species have been demonstrated to acquire venom toxins from other sources, notably from associated microbes, which may even inhabit their venom apparatuses. Venoms adapt to their environment and victims, evolving to become maximally efficient on a predator's particular prey (particularly the precise ion channels within the prey). Consequently, some venoms may become specialized to an animal's standard diet.
=== Genetics === sIBM is not inherited and is not passed on to the children of IBM patients. There are genetic features that do not directly cause IBM but that appear to predispose a person to getting IBM – having this particular combination of genes increases one's susceptibility to getting IBM. Some 67% of IBM patients have a particular combination of human leukocyte antigen genes in a section of the 8.1 ancestral haplotype in the center of the MHC class II region. sIBM is not passed on from generation to generation, although the susceptibility region of genes may be. There are also several rare forms of hereditary inclusion body myopathy that are linked to specific genetic defects and that are passed on from generation to generation. Since these forms do not show features of muscle inflammation, they are classified as myopathies rather than forms of myositis. Because they do not display inflammation as a primary symptom, they may in fact be similar, but different diseases to sporadic inclusion body myositis. There are several different types, each inherited in different ways. See hereditary inclusion body myopathy. A 2007 review concluded there is no indication that the genes responsible for the familial or hereditary conditions are involved in sIBM.
To ensure early detection, all individuals with MCTD must have screening echocardiography and high-resolution computed tomography upon diagnosis. Mild cases require regular testing to monitor for progression. Traditional therapies such as calcium channel blockers, ACE inhibitors, immunosuppression, and heart failure medications can be used. Pericarditis is typically treated with NSAIDs and/or corticosteroids based on severity. For moderate to severe myocarditis, high-dose steroid therapy should be combined with standard congestive heart failure treatment. Treatment for gastrointestinal problems in MCTD is identical to that for systemic sclerosis. First-line treatment for chronic reflux symptoms includes proton-pump inhibitors, H2-receptor antagonists, lifestyle changes, and oesophageal PH monitoring. Kidney involvement can lead to nephrotic syndrome, which may be treated with high-dose corticosteroid therapy. Corticosteroids are used to treat nervous system involvement in low-dose oral, high-dose oral, or high-dose intravenous regimens, depending on the severity of the potential harm.
Sources: en.wikipedia.org
In cell biology, a granule is a small particle barely visible by light microscopy. The term is most often used to describe a secretory vesicle containing important components of cell physiology. Examples of granules include platelet granules and insulin granules. Some granules such as the ones mentioned are considered organelles, other such as starch granules are not.
Category:Liberal Party (UK) MPs List of Liberal Party (UK) MPs Liberalism in the United Kingdom Liberal Democrats Leader of the Liberal Party (UK) List of United Kingdom Whig and allied party leaders, 1801–1859 Liberal Chief Whip President of the Liberal Party List of Liberal Party and Liberal Democrats (UK) general election manifestos
"Absorption spectrum of melanin". Department of Computer Science and Technology. "Tyrosine metabolism—Reference pathway". Kyoto Encyclopedia of Genes and Genomes. Retrieved 13 June 2024. "Melanogenesis". Kyoto Encyclopedia of Genes and Genomes. Retrieved 13 June 2024.
Before analyzing with mass spectrometry, a protein must be accurately isolated and digested. If not isolated, the results will represent a mixture of two or more proteins and will therefore be unreliable in protein identification. Because of this sensitivity, sample preparation is likely the most important step in forming a peptide-mass fingerprint. Isolation of a specific protein is most often done through a form of gel electrophoresis, in which proteins are separated by size and can be subsequently extracted for further preparation. However, they can also be isolated by liquid chromatography. This method also separates proteins by size. Once an individual protein is isolated, it needs to be digested and fractionated for further analysis by a spectrometer. This is done by the addition of proteolytic enzymes such as trypsin and chymotrypsin. Another method commonly used that combines both the isolation and digestion steps is SDS-PAGE, a form of electrophoresis that separates and fractionates proteins simultaneously.
== Early political career (1959–1970) == After World War II ended and the Japanese withdrew, the British grouped the Malay states and the Straits Settlements into the Malayan Union, and granted citizenship to non-Malays. This caused major backlash from Malays and a wave of Malay nationalism swept across the country. Mahathir became politically activated by these changes, joining protests and activism against the new citizenship policies. Mahathir later argued for affirmative action for Malays at medical college. While at college, he contributed to The Straits Times under the pseudonym "C.H.E. Det" and a student journal, in which he fiercely promoted Malay rights, such as calling for the restoration of Malay as an official language. While practising as a physician in Alor Setar, Mahathir became active in UMNO. His earliest political involvement was in the Kampung Charok Kudong Umno branch, where he made his debut in politics. By the time of the first general election for the independent state of Malaya in 1959, he was the chairman of the party in Kedah. Despite his prominence in UMNO, Mahathir was not a candidate in the 1959 election, ruling himself out following a disagreement with then Prime Minister Tunku Abdul Rahman. Their relationship had been strained since Mahathir had criticised Tunku's agreement to retain British and Commonwealth forces in Malaya after independence. Tunku opposed Mahathir's plans to introduce minimum educational qualifications for UMNO candidates.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.